/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. AI For Pharma Growth
  2. E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner
E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth · Aug 25, 2026

Upgrade interim analysis with predictive modeling to catch clinical trial futility and success years sooner, saving resources and accelerating drugs to market.

Most Phase 2/3 Trials Skip Pre-Planned Interim Analyses, Forgoing Early Futility Signals

Despite their potential to save time and money, a large majority of commercial Phase 2 and 3 clinical trials in 2023 did not include a pre-planned interim analysis. This indicates a massive, underutilized opportunity to identify failing drugs sooner and reallocate resources more effectively.

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner thumbnail

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth·3 months ago

AI's Unpredictability Makes It Unsuitable for Core Trial Stop/Go Decisions

For high-stakes decisions like halting a clinical trial, current AI models lack the reproducibility and explainability demanded by regulators. The 'Brakes' platform deliberately avoids AI in its core decision engine, applying it instead to adjacent problems like patient subgroup analysis where the stakes for error are different.

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner thumbnail

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth·3 months ago

Early Success Signals Should Drive Business Intelligence, Not Just Halt Trials

Instead of stopping a trial early for success—which regulators may restrict—a high-confidence early signal provides immense value as business intelligence. This allows sponsors to de-risk and accelerate planning for subsequent phases months earlier, creating millions in value by reducing the gap between Phase 2 and 3.

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner thumbnail

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth·3 months ago

Advanced Interim Analyses Use a Human-Free 'Enclave' to Process Unblinded Data Safely

To maintain trial integrity while using predictive algorithms, unblinded data must be handled within a secure, isolated computing architecture. This 'enclave' prevents any human—including statisticians, doctors, or the analysts themselves—from accessing the data, thus eliminating the risk of operational bias.

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner thumbnail

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth·3 months ago

Defining Precise Patient Subgroups Risks Weakening a Trial's Statistical Power

AI can identify patient subgroups that respond best to a drug, but this creates a paradox. The more narrowly the group is defined, the smaller it becomes, which weakens the trial's statistical power to detect an effect. The core challenge is optimizing the trade-off between signal clarity and statistical viability.

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner thumbnail

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth·3 months ago

Stopping a Trial Late Still Yields Savings, as Up to 80% of Costs Are Linear

Contrary to the belief that trial costs are entirely front-loaded, a significant portion—potentially 80%—are marginal and scale with patient progression. Therefore, making a futility call even late in a trial can still generate substantial cost savings, challenging conventional financial assumptions about trial budgeting.

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner thumbnail

E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner

AI For Pharma Growth·3 months ago